drug: bupropion
- Clinical class: anti-depressant; smoking cessation aid
- Action: selective dopamine-reuptake inhibitor
- Chemical class: monocyclic amino ketone
- CSA schedule: none
- DEA number: none
- Also: amfebutamone
- MEDLINEplus® Drug Information
U.S. Preparations:
-
Aplenzin™ (Biovail) FDA approved:
4.23.2008 - Budeprion™ SR (Teva)
- Buproban™ (Teva)
- Wellbutrin® (GlaxoSmithKline) FDA approved:
12.30.1985 -
Wellbutrin SR® (GlaxoSmithKline) FDA approved:
10.4.1996 for treatment of depression (SR)
U.S. prescribing information
- Wellbutrin XL® (GlaxoSmithKline) FDA approved:
8.29.2003 for treatment of Major Depressive Disorder
6.12.2006 for the prevention of seasonal Major Depressive Episodes in patients with a diagnosis of seasonal affective disorder
U.S. prescribing information - Zyban® (GlaxoSmithKline) FDA approved:
5.14.1997 for smoking cessation
U.S. prescribing information
Stephen Stahl's Clinical Pearls* (Consult your physician before making any change in your treatment.)
- Can add to SSRIs to reverse SSRI sexual dysfunction.
- Can add to SSRIs to boost inadequate efficacy.
- Can switch SSRI secondary refractory patients to reattain efficacy.
- New controlled release formulation for twice daily and possibly once daily administration.
- Use in adult and childhood ADD (attention deficit disorder).
- Effective for use in smoking cessation (treatment of nicotine dependence).
- May be useful for treating stimulant withdrawal and craving.
|
|
Books and Other Media: Follow the hypertext link to purchase items. |
|
*Reprinted with permission from: Stahl, Stephen M Psychopharmacology of Antidepressants Paperback 1997 Martin Dunitz, Ltd & Blackwell Science You cannot fully appreciate this book until you have seen the extraordinary illustrations of every aspect of this area of psychopharmacology and neurochemistry. Loaded with practical clinical "pearls."